JPMorgan Identifies Top EU Pharma, Biotech & Life Science Stocks for 2026 with AstraZeneca Leading Rankings
Friday, January 02, 2026
JPMorgan's latest analysis positions the European pharmaceutical, biotechnology, and life sciences sector for substantial growth in 2026, naming several standout companies expected to outperform peers. Leading the rankings is **AstraZeneca**, forecasted for best-in-sector low double-digit Core EPS growth despite challenges like the Farxiga patent expiration. The company's robust pipeline offers approximately $12 billion in risk-adjusted peak sales potential from upcoming drug readouts. Analysts project AstraZeneca to achieve $80 billion in revenues by 2030, maintaining an Overweight rating with a £160 price target. Recent developments include the U.S. FDA's priority review acceptance for baxdrostat, a hypertension treatment, alongside Morgan Stanley raising its price target due to sector-leading earnings growth.
In second place, **Novartis** anticipates medium-term upgrades fueled by strong sales from Kisqali, Kesimpta, and Pluvicto. Although 2026 growth might be moderated by Entresto generics, four major pipeline readouts could each trigger multi-billion dollar sales forecast revisions. JPMorgan upgraded Novartis to Overweight with a SFr125 price target. Novartis recently announced a $120 million upfront collaboration with Monte Rosa Therapeutics for immune-mediated diseases and received a Buy rating reiteration from Deutsche Bank after an RNA deal.
**Bayer** secures third position, with improvements in both Crop and Pharma divisions supporting a strong 2027-2030 growth outlook. Trading at 5x 2027E EV/EBITDA, its valuation appears undervalued amid new product cycles and potential glyphosate litigation relief. JPMorgan rates it Overweight at €50. Bayer's menopause drug Lynkuet gained European regulatory backing, nearing EU approval, and the company extended its partnership with Ginkgo Bioworks for agricultural biologicals.
Among biotechs, **Argenx** stands out with Vyvgart sales momentum driving 39% year-over-year revenue growth to $5.7 billion in 2026, bolstered by five registrational trials. Overweight rating with €950 target. **UCB** expects Bimzelx upgrades post-Hidradenitis Suppurativa launch, forecasting €8,384 million revenues, Overweight at €300. **Zealand Pharma** features petrelintide Phase II data in obesity trials mid-2026, Overweight at DKr1,000.
In life sciences, **Lonza** leads with 10-13% CDMO growth and margin expansion, Overweight at SFr675. **Sartorius Group** projects high-single-digit sales growth, targets €295/€270. **Bachem** anticipates over 35% revenue acceleration from Building K ramp-up, Overweight at SFr85.
This outlook underscores strategic opportunities for executives in R&D investments, partnerships, and manufacturing expansions across Europe. Companies like AstraZeneca exemplify resilience through pipeline diversification, while biotechs like Argenx highlight innovation in high-growth areas. Investors should monitor regulatory progresses, such as Bayer's EU advancements, and pipeline catalysts for Novartis and Zealand. Overall, JPMorgan's selections reflect a sector poised for upgrades amid improving fundamentals, emphasizing the importance of **biopharma innovations**, **clinical trials**, and **strategy** in sustaining European leadership. For pharma leaders, these insights guide portfolio prioritization, M&A considerations, and supply chain optimizations in a competitive landscape.
Further details reveal AstraZeneca's oncology and cardiovascular focus bolstering long-term projections, Novartis' immunology strengths mitigating generic pressures, and Bayer's dual-division recovery enhancing stability. Biotech momentum at Argenx and UCB signals immunology and dermatology hotspots, while Lonza's CDMO prowess addresses manufacturing demands. This comprehensive ranking aids stakeholders in navigating 2026 dynamics, from **regulations** to **digital health integrations** in pharma operations.
